10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

BCL10 (MALT-Lymphoma Marker) Antibody - With BSA and Azide

Mouse Monoclonal Antibody [Clone SPM520]

Catalog # AH10829

Specification

BCL10 (MALT-Lymphoma Marker) Antibody - With BSA and Azide - Product Information

Application	**,1,14,3,4,**
Primary Accession	O95999
Other Accession	8915, 193516
Reactivity	**Human**
Host	**Mouse**
Clonality	**Monoclonal**
Isotype	**Mouse / IgG1, kappa**
Calculated MW	**33kDa KDa**

BCL10 (MALT-Lymphoma Marker) Antibody - With BSA and Azide - Additional Information

Gene ID 8915

Other Names
B-cell lymphoma/leukemia 10, B-cell CLL/lymphoma 10, Bcl-10, CARD-containing molecule enhancing NF-kappa-B, CARD-like apoptotic protein, hCLAP, CED-3/ICH-1 prodomain homologous E10-like regulator, CIPER, Cellular homolog of vCARMEN, cCARMEN, Cellular-E10, c-E10, Mammalian CARD-containing adapter molecule E10, mE10, BCL10, CIPER, CLAP

Format
200ug/ml of Ab purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.

Storage
Store at 2 to 8°C.Antibody is stable for 24 months.

Precautions
BCL10 (MALT-Lymphoma Marker) Antibody - With BSA and Azide is for research use only and not for use in diagnostic or therapeutic procedures.

BCL10 (MALT-Lymphoma Marker) Antibody - With BSA and Azide - Protein Information

Name BCL10 {ECO:0000303|PubMed:9989495, ECO:0000312|HGNC:HGNC:989}

Function
Plays a key role in both adaptive and innate immune signaling by bridging CARD domain-containing proteins to immune activation (PubMed:10187770, PubMed:10364242, PubMed:10400625, PubMed:24074955, PubMed:<a

href="http://www.uniprot.org/citations/25365219" target="_blank">25365219). Acts by channeling adaptive and innate immune signaling downstream of CARD domain-containing proteins CARD9, CARD11 and CARD14 to activate NF-kappa-B and MAP kinase p38 (MAPK11, MAPK12, MAPK13 and/or MAPK14) pathways which stimulate expression of genes encoding pro-inflammatory cytokines and chemokines (PubMed:24074955). Recruited by activated CARD domain-containing proteins: homooligomerized CARD domain-containing proteins form a nucleating helical template that recruits BCL10 via CARD-CARD interaction, thereby promoting polymerization of BCL10, subsequent recruitment of MALT1 and formation of a CBM complex (PubMed:24074955). This leads to activation of NF-kappa-B and MAP kinase p38 (MAPK11, MAPK12, MAPK13 and/or MAPK14) pathways which stimulate expression of genes encoding pro-inflammatory cytokines and chemokines (PubMed:18287044, PubMed:24074955, PubMed:27777308). Activated by CARD9 downstream of C-type lectin receptors; CARD9-mediated signals are essential for antifungal immunity (PubMed:26488816). Activated by CARD11 downstream of T-cell receptor (TCR) and B-cell receptor (BCR) (PubMed:18264101, PubMed:18287044, PubMed:24074955, PubMed:27777308). Promotes apoptosis, pro-caspase-9 maturation and activation of NF-kappa-B via NIK and IKK (PubMed:10187815).

Cellular Location
Cytoplasm, perinuclear region. Membrane raft. Note=Appears to have a perinuclear, compact and filamentous pattern of expression. Also found in the nucleus of several types of tumor cells. Colocalized with DPP4 in membrane rafts.

Tissue Location
Ubiquitous..

BCL10 (MALT-Lymphoma Marker) Antibody - With BSA and Azide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

BCL10 (MALT-Lymphoma Marker) Antibody - With BSA and Azide - Images

10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999



Formalin-fixed, paraffin-embedded human Tonsil stained with BCL10 Monoclonal Antibody (SPM520).

BCL10 (MALT-Lymphoma Marker) Antibody - With BSA and Azide - Background

BCL10, with an N-terminal caspase recruitment domain (CARD), is found in a number of apoptotic regulatory molecules. It was identified through its direct involvement in t(1;14) of mucosa-associated lymphoid tissue (MALT) lymphoma. Expression of BCL10 was shown to induce NFĪŗB activation in a NIK-dependent pathway. This MAb labels subpopulations of normal B and T cells and is a useful tool for the sub-classification of lymphomas. In MALT lymphomas with the t(1;14) translocation, while 55% of MALT lymphomas lacking this translocation exhibited the same labeling pattern, although at a much lower level.

BCL10 (MALT-Lymphoma Marker) Antibody - With BSA and Azide - References

Ye H et. al. Am J Pathol 2000;157:1147-54